MedCity News November 13, 2024
Frank Vinluan

Johnson & Johnson is suing the federal agencies overseeing the 340B program that makes discounted medicines more accessible to uninsured and underserved patients. J&J contends the Health Resources Services Administration can’t legally oppose its plan to implement a new rebate plan for certain 340B drugs.

When Johnson & Johnson backed down from its proposal to modify the way it supplies certain drugs under the 340B statute, it hinted litigation could be its next step to effect changes that address what it says is rampant abuse of a program originally intended to make medicines more accessible to underserved patients. The pharmaceutical giant has now taken that legal step.

J&J is suing the Department of Health and Human Services and the Health...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Pharma, Pharma / Biotech, Provider
Related Articles:
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Pharma At A Crossroads: Navigating Cost Pressures And Regulatory Shifts In 2025
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease

Share This Article